MedPath

Pioglitazone

These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS. PIOGLITAZONE tablets, for oral use Initial U.S. Approval: 1999

Approved
Approval ID

fbdaaa34-06c4-49af-85b4-91a85922b30b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 9, 2022

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Pioglitazone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71335-1333
Application NumberANDA077210
Product Classification
M
Marketing Category
C73584
G
Generic Name
Pioglitazone
Product Specifications
Route of AdministrationORAL
Effective DateAugust 14, 2021
FDA Product Classification

INGREDIENTS (5)

PIOGLITAZONE HYDROCHLORIDEActive
Quantity: 30 mg in 1 1
Code: JQT35NPK6C
Classification: ACTIM
CARBOXYMETHYLCELLULOSE CALCIUMInactive
Code: UTY7PDF93L
Classification: IACT
HYDROXYPROPYL CELLULOSE (1600000 WAMW)Inactive
Code: RFW2ET671P
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Pioglitazone - FDA Drug Approval Details